Connect with us

Technology

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Published

2 years ago

on

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care

LONDON, Jan. 8, 2025 /PRNewswire/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years. Since its inception, Drugs to Watch has identified over 98 transformative therapies, cementing its role as an essential resource for navigating the ever-evolving pharmaceutical landscape.

This year’s report, powered by insights from the Clarivate Cortellis intelligence suite of products, highlights 11 therapies that have recently launched or are set to debut in 2025. These innovations, addressing critical challenges in areas such as obesity, oncology, and gene therapy, are forecast to achieve blockbuster sales by 2030 or dramatically improve patient outcomes on a global scale. The report also explores pivotal trends shaping the industry, including the surging demand for obesity treatments, the transformative potential of gene editing, and the growing impact of regulatory innovation.

The report offers an in-depth analysis of the chronic disease market in Mainland China, spotlighting five therapies expected to exceed $1 billion in annual sales over the next five years or deliver transformative outcomes for patients. It also explores critical topics shaping global healthcare, including regulatory advancements, the role of radiopharmaceutical theranostics in oncology, and the growing use of real-world data (RWD) and patient-reported outcomes (PROs) to drive health equity and enhance regulatory submissions.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, remarked: “Innovation in the life sciences is reaching unprecedented heights, and this year’s Drugs to Watch™ report once again demonstrates the industry’s ability to deliver therapies that address unmet medical needs and challenge existing paradigms of care. At Clarivate, we take pride in the precision and reliability of our predictions—last year, we identified 13 molecules as Drugs to Watch, with 12 already approved and launched and one poised for launch. This track record reflects the strength of our comprehensive data and deep expertise. By continuing to provide actionable insights, we empower the sector to navigate opportunities, overcome challenges and drive progress in advancing global health.”

Mike Ward, Global Head of Thought Leadership, Life Sciences & Healthcare, Clarivate, stated: “2025 represents a turning point for the life sciences sector as it embraces cutting-edge technologies such as AI and machine learning to enhance drug discovery and development. This year’s report captures the dynamic forces at play, including groundbreaking progress in precision oncology, the rise of radiopharmaceuticals, and the growing focus on addressing global health disparities.”

The 2025 Drugs to Watch™ report highlights key trends reshaping the life sciences landscape, emphasizing the transformative impact of emerging technologies and therapeutic breakthroughs. Advances in AI and machine learning are streamlining drug discovery, clinical trials, and real-world data integration, enabling precision medicine approaches. The obesity market is undergoing a revolution driven by next-generation GLP-1 therapies, while radiopharmaceutical theranostics are redefining cancer treatment with a “see it and treat it” paradigm. Gene editing technologies are unlocking new opportunities in personalized medicine, and evolving regulatory frameworks are fostering greater emphasis on patient-reported outcomes and health equity. Together, these trends showcase the sector’s resilience and its ability to navigate challenges while driving innovation to improve patient care worldwide.

This year’s drugs to watch exemplify the fusion of innovation and dedication to advancing patient care in an increasingly complex healthcare ecosystem. The Drugs to Watch™ 2025 list include:

AWIQLI® (LAI 287; insulin icodec) developed by Novo Nordisk | Type 1 and type 2 diabetes mellitus 
AWIQLI®, the first once-weekly, subcutaneous insulin, has launched in Australia, Canada, the EU, Mainland China, and Japan. Its weekly dosing offers a significant advantage over daily basal insulin, potentially reducing the treatment burden for patients with type 1 or type 2 diabetes (T1DM and T2DM).

CagriSema (cagrilintide + semaglutide) developed by Novo Nordisk | Obesity and type 2 diabetes mellitus 
CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (OZEMPIC/WEGOVY®) and tirzepatide (MOUNJARO/ZEPBOUND®) in treating obesity and type 2 diabetes. This next-generation GLP-1 therapy leverages the benefits of GLP-1s, such as enhanced insulin secretion and appetite reduction, while incorporating amylin’s effects, including slowed glucose absorption and release. If approved, CagriSema will be the first fixed-dose combination of amylin and GLP-1 receptor agonists in the obesity and T2DM markets.

COBENFY™ (KarXT; xanomeline-trospium) developed by Bristol Myers Squibb | Schizophrenia and psychosis related to Alzheimer’s disease
Amid setbacks for emerging schizophrenia treatments, the approval of COBENFY marks a transformative milestone as the first drug in over 30 years with a novel mechanism of action for treating schizophrenia. Combining xanomeline and trospium, COBENFY selectively targets M1 and M4 receptors, rather than traditional dopamine pathways, while minimizing cholinergic side effects. While further data is needed to assess its effectiveness in Alzheimer’s disease-related psychosis, COBENFY shows strong commercial potential if proven effective in treating AD-related hallucinations and delusions.

EBGLYSS™ (lebrikizumab) developed by Eli Lilly and Co and Almirall | Atopic dermatitis
EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab) and ADBRY®/ADTRALZA® (tralokinumab) to market. Its less frequent dosing, more selective IL-13 inhibition, and strong efficacy and safety data position it as a likely first-line treatment for moderate-to-severe atopic dermatitis when topical corticosteroids are inadequate.

Fitusiran developed by Alnylam® Pharmaceuticals Inc and Sanofi | Hemophilia A and B
Fitusiran, shown to be effective in phase 3 trials for both hemophilia A and B, regardless of inhibitor status, has the potential to offer a new approach to hemophilia treatment. This small interfering RNA (siRNA) therapy works by inhibiting SerpinPC1 mRNA, reducing antithrombin levels, promoting thrombin generation, and helping to rebalance hemostasis to prevent bleeds. Leveraging Alnylam® Pharmaceuticals’ ESC-GalNAc conjugate technology, fitusiran could become the first antithrombin-lowering therapy based on a double-stranded RNA molecule, pending approval.

GSK-3536819 (MenABCWY) developed by GSK plc | Meningococcus
GSK plc’s GSK-3536819 vaccine candidate, a 5-in-1, first-generation formulation, targets the five groups of Neisseria meningitidis (A, B, C, W, and Y) responsible for most invasive meningococcal disease (IMD) cases worldwide. It combines the antigenic components of GSK’s licensed meningococcal vaccines, BEXSERO (MenB) and MENVEO (MenACWY), both of which have established efficacy and safety profiles.

IMDELLTRA™ (tarlatamab-dlle) developed by Amgen | Small-cell lung cancer (SCLC)
IMDELLTRA™ is a first-in-class immunotherapy for extensive-stage small cell lung cancer (ES-SCLC). Using Amgen’s bispecific T cell engager (BiTE®) molecules, it targets CD3 on T cells and DLL3 on tumor cells, enabling T cells to attack and lyse the tumor. DLL3 is expressed on the surface of SCLC cells in more than 85% of patients but is minimally expressed on healthy cells making it an attractive target. This mechanism positions IMDELLTRA as a potential standard of care for previously treated ES-SCLC.

mRESVIA (mRNA-1345) developed by Moderna Inc | RSV
With its U.S. FDA approval in May 2024, mRESVIA® joined AREXVY and ABRYSVO, both featured in Drugs to Watch 2024, as respiratory syncytial virus (RSV) vaccines currently available for adults ages 60 years and older, helping further support the public health initiative to reduce the RSV-related disease burden. Even with available vaccines, RSV infections continue to be a public health concern, particularly for infants and older adults (65 years and older).

SEL-212 developed by Sobi® and Cartesian Therapeutics Inc/Selecta Biosciences Inc | Gout
SEL-212 is a novel, once-monthly treatment combining pegylated uricase (pegadricase; SEL-037) with ImmTOR™, an immune tolerance technology designed to inhibit the formation of anti-drug antibodies (ADAs). For this application, ImmTOR consists of SEL-110.36, an inhibitor of uricase-specific ADA. This approach may help overcome the limitations of reduced efficacy and tolerability seen with other biologic treatments, such as KRYSTEXXA® (pegloticase), in patients with chronic gout.

Vepdegestrant (ARV-471) developed by Arvinas Inc and Pfizer Inc | Breast cancer
A global collaboration between Arvinas Inc and Pfizer Inc, vepdegestrant may become the first PROteolysis Targeting Chimera (PROTAC®) protein degrader on the market. Designed to target and degrade the estrogen receptor (ER) protein, early studies suggest PROTAC-induced degradation is more complete than with oral selective estrogen receptor degraders (SERDs). This offers potential for overcoming endocrine resistance in breast cancer. Label expansions, including combination with IBRANCE® (palbociclib), are being explored.

Zanzalintinib (XL092) developed by Exelixis Inc | Colorectal cancer, renal cell carcinoma and squamous cell carcinoma of head and neck
Zanzalintinib is a third-generation oral tyrosine kinase inhibitor targeting VEGF receptors, MET, and TAM kinases involved in tumor growth and immunosuppression. Currently in phase 3 trials for non-clear-cell renal cell carcinoma (nccRCC), colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN), the company anticipates one potential zanzalintinib launch per year starting as early as 2026. Compared to CABOMETYX® (cabozantinib), zanzalintinib may offer benefits, including approval for nccRCC histology and a broader patient population.

Access the Drugs to Watch 2025 report from Clarivate, here.

For more Drugs to Watch updates and analyses throughout the year, visit the Drugs to Watch web page and follow Clarivate for Life Sciences & Healthcare on LinkedIn and X. Join the conversation, using #DrugstoWatch.

To learn more about how Clarivate can help healthcare companies inform and shape the drug discovery, development and delivery process, visit here.

Methodology for the Clarivate Drugs to Watch 2025 Report
To identify this year’s Drugs to Watch, Clarivate drew from the expertise of over 160 analysts covering hundreds of diseases, drugs and markets, along with 11 integrated data sets that span the R&D and commercialization lifecycle, including: Cortellis Competitive Intelligence™, Disease Landscape & Forecast, Epidemiology Intelligence, BioWorld™, Cortellis Regulatory Intelligence™, Drug Timeline & Success Rates, Cortellis Clinical Trials Intelligence™, Cortellis Deals Intelligence™,  Access & Reimbursement payer studies, Clarivate Real-World Data and Analytics, Web of Science™, Derwent Innovation™, and other industry sources including biopharma company press releases, filings and peer-reviewed publications. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched in 2024 were selected for analysis, including both novel treatments and already-marketed drugs pursuing new indications that could be particularly impactful. Drugs launched prior to 2024 were excluded. The dataset was filtered for drugs that had total forecast sales of $1 billion or more by 2030. Clarivate experts and analysts evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other key factors, and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers.

Please note that Clarivate analysts generated the data shown in this report prior to December 31, 2024. The Drugs to Watch 2025 Report and the treatments referenced in this release are based on Clarivate’s current expectations per existing data, but actual results derived from the drugs named in the report and here may differ significantly.

Clarivate is committed to comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health. By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, data-driven decisions and accelerating innovation, Clarivate’s end-to-end research intelligence is designed to enable customers to make informed evidence-based decisions. 

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.

Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

SOURCE Clarivate Plc

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Cambium Networks Introduces High Density Wi-Fi 7 Solution for the Enterprise

Published

52 minutes ago

on

July 22, 2026

By

New tri-band, software-definable Wi-Fi 7 solution delivers precision directive coverage with AI optimization for exhibition halls, auditoriums, warehouses, and other high-density environments.

HOFFMAN ESTATES, Ill., July 22, 2026 /PRNewswire/ — Cambium Networks, a leading global provider of networking solutions, today announced a new Wi-Fi 7 high-density access point – the X7-56X – engineered to deliver high-performance wireless connectivity in the most demanding environments. Designed to meet the needs of large public venues, exhibition halls, busy public spaces, and educational campuses, the solution combines focused RF coverage, AI-driven optimization, and cloud-managed simplicity in a high-capacity platform.

The X7-56X extends Cambium Networks’ Wi-Fi 7 portfolio with a software-definable tri-band architecture featuring 60° x 60° directive antennas designed for precision coverage and reduced co-channel interference in congested RF environments. The platform supports up to 1,280 clients per access point and up to 17.9 Gbps aggregate wireless capacity across the three Wi-Fi spectrum bands.

“The X7-56X performed very well in our ticket scanning points that have high ceilings and see significant foot traffic volume,” said Jonathan West from the National Ice Centre in Nottingham, UK. “What makes this AP practical for a venue like ours is the integrated 60×60 degree antennas that eliminate separate antennas and cabling and can add significant cost, complexity, and footprint to every mount. Engineering all of that into one unit expedites installation and improves aesthetics as well. This form factor will extend to applications in our seating bowl as well.” 

“What excites me about the X7-56X is how well its directional approach works for some of our toughest spaces, such as auditoriums at capacity or the basketball arena on game night,” said Jeremy Petticrew, Network Engineer at University of Mary Hardin-Baylor. “Precisely controlling Wi-Fi coverage has always been the hard part, and having an AP designed specifically for that, inside a platform we already trust, is a real advantage as device counts keep climbing.”

The X7-56X integrates with Cambium’s ONE Network architecture comprised of Wi-Fi, switching, security, SD-WAN, wireless backhaul, and fiber – all managed through the cloud via cnMaestro™ X. This unified approach provides centralized visibility and control across the entire network infrastructure from a single source of truth.

The new solution provides a compelling Total Cost of Ownership (TCO) proposition by reducing the amount of equipment required in typical installations. These advantages are enabled by:

Directive antennas that focus Wi-Fi coverage only where needed – a spotlight approach vs. the floodlight type of inefficiencies of omni-directional antennas

Integrated Wi-Fi controller in every AP, eliminating the need for separate appliance or VM-based controller solutions

Software-defined radios that enable flexible deployment of the 5GHz and 6GHz Wi-Fi bands matched to environment needs, reducing the number of APs required

Key capabilities of the X7-56X include:

Tri-radio, tri-band Wi-Fi 7 architecture

4×4 MU-MIMO support with ten total spatial streams

60° x 60° directive antenna for precision coverage

Air Cleaner technology for high-density RF optimization

AI-based Assurance for improved operational efficiency and problem resolution

Software-definable radios supporting flexible 5 GHz and 6 GHz migration

Built-in IoT radio supporting BLE 5.1, Zigbee, Matter, and Thread

Simplified installation with the MarketApps Installer mobile-based app and flexible mounting options

Cloud-based management through cnMaestro™

“High-performance Wi-Fi requires more than just raw throughput,” said Bruce Miller, VP Enterprise Product Management at Cambium Networks. “Intelligent RF management, flexible deployment options, and simplified operations are key to support growing device counts, IoT proliferation, and AI-powered applications. The X7-56X was purpose-built for these challenges while at the same time delivering compelling economics for enterprise IT and managed service providers.”

“The X7-56X brings together several technologies that are particularly valuable in high-density environments,” said Kevin Tolly, Founder of The Tolly Group. “The directive antenna design, Wi-Fi 7 architecture, integrated IoT capabilities, and cloud-managed operation provide organizations with a practical approach to supporting growing connectivity requirements while maintaining operational simplicity.”

View the Tolly Group preview video of the X7-56X, showcasing the access point’s ultra-high-density design, Wi-Fi 7 capabilities, deployment flexibility, and performance advantages for demanding enterprise environments.

Cambium Networks’ directional Wi-Fi 7 innovation was recently highlighted by Wi-Fi NOW in an Expert Insights article by CEO and Chairman Claus Hetting.

Watch our webinar replay, “High-Performance Wi-Fi with New Wi-Fi 7 and 6 GHz Solutions.”

About Cambium Networks

Cambium Networks enables service providers, enterprises, industrial organizations, and governments to deliver exceptional digital experiences, and device connectivity, with compelling economics. Our ONE Network platform simplifies management of Cambium Networks’ wired and wireless broadband and network edge technologies. Our customers can focus more resources on managing their business rather than the network. We make connectivity that just works.

Media Contact

pr@cambiumnetworks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cambium-networks-introduces-high-density-wi-fi-7-solution-for-the-enterprise-302832358.html

SOURCE Cambium Networks

Continue Reading

Technology

OCEAN Launches Portal, the First End-to-End Encrypted Pool Dashboard for Bitcoin Miners

Published

52 minutes ago

on

July 22, 2026

By

New customizable dashboard gives miners operation-wide tools without surrendering privacy or identity

MIAMI, July 22, 2026 /PRNewswire/ — Today OCEAN announced the launch of OCEAN Portal, a customizable, end-to-end encrypted dashboard that gives Bitcoin miners a complete view of their operation. PORTAL was unveiled on stage at Mining Disrupt 2026, the world’s largest Bitcoin mining expo and conference, held July 21-23 at the Miami Airport Convention Center, by OCEAN President Mark Artymko. PORTAL is available now, for free, to all miners on OCEAN at portal.ocean.xyz.

OCEAN was built permissionless from the ground up, a deliberate design choice that, like Bitcoin itself, gives miners unhindered access to their own information. Traditional pools organize miner data by storing it on their own servers. OCEAN Portal delivers that same organized, polished experience while keeping miners fully in control: a permissionless, encrypted view of your mining addresses with the look and feel of an enterprise-style dashboard. Miners can combine multiple Bitcoin addresses into a single view, organize addresses by site, and assign human-readable names to sites, workers, and teams. Portal includes site-specific statistics, worker insights, payout information in Bitcoin and fiat, robust reporting tools, and access controls that let operators share full dashboards with their teams or generate expiring read-only links for clients. No account or email is required. Miners sign in with a Bitcoin address and a password they create. The convenience of enterprise dashboards, with the security of OCEAN.

“PORTAL was built in direct response to miner feedback,” said Mark Artymko, President of OCEAN. “Some of our miners told us that a customizable dashboard was the only thing standing between their full stack of hashrate and the pool. OCEAN heard them, and built it.”

PORTAL is powered by Sub-space Locker, an application-independent encrypted storage and access-control system developed by OCEAN. Built on public-key cryptography, Sub-space Locker authenticates users, stores encrypted application data, and controls what each user can access. Encryption and decryption happen locally in the user’s browser, leaving OCEAN and other intermediaries unable to read the underlying data.

“Every mining pool dashboard on earth makes the same trade: your tooling for your identity,” said Jason Hughes, VP of Engineering at OCEAN. “PORTAL refuses that trade. Miners get pool-grade information in the most sovereign way possible. We couldn’t read their data even if we tried.”

Since launching in 2023, OCEAN has focused on returning sovereignty to Bitcoin miners through permissionless, non-custodial pooled mining, fully transparent and auditable TIDES payouts, and DATUM, which puts block template construction back in miners’ hands. PORTAL extends that mission from the pool to the mining operation itself.

OCEAN Portal is available now at portal.ocean.xyz.

About OCEAN

OCEAN is a Bitcoin mining pool built on miner sovereignty. Operated by Mummolin, Inc., OCEAN offers non-custodial payouts, transparent reward accounting, and DATUM, the only pool technology that lets individual miners construct their own block templates.

Media Contact Ian Northon media@ocean.xyz

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ocean-launches-portal-the-first-end-to-end-encrypted-pool-dashboard-for-bitcoin-miners-302831868.html

SOURCE Mummolin Inc

Continue Reading

Technology

PlayVS and Scouting America Announce Gaming Activation at the 2026 National Jamboree

Published

52 minutes ago

on

July 22, 2026

By

New immersive gaming hub will bring structured esports competition, casual play, and digital citizenship programming to Scouts at Summit Bechtel Reserve

LOS ANGELES, July 22, 2026 /PRNewswire/ — PlayVS, North America’s leading scholastic gaming platform, today announced a partnership with Scouting America to bring a state-of-the-art gaming activation to the 2026 National Jamboree, taking place July 22–31, 2026. One of Scouting America’s premier youth gatherings, the National Jamboree at Summit Bechtel Reserve in West Virginia, brings Scouts together from across the country for adventure, fellowship, skill-building, and shared experiences.

Running throughout the National Jamboree, the PlayVS Arena will offer a rotating schedule of competitive tournaments, leaderboard challenges, casual gaming, and hands-on technology experiences. Designed for Scouts of all experience levels, the activation promotes teamwork, digital citizenship, sportsmanship, and healthy competition while creating a welcoming space for Scouts to connect over a shared passion for gaming. The arena gives Scouts the opportunity to connect with friends, test their skills, and experience organized esports in an environment designed for participation, sportsmanship, and fun.

“At PlayVS, we believe gaming can be a powerful way for young people to build confidence, practice teamwork, and develop meaningful connections,” said Andrew Barnett, Partnership Lead. “Partnering with Scouting America allows us to bring that experience to one of the country’s most iconic youth gatherings and show how structured gaming can complement the values of leadership, fellowship, and skill-building that Scouting has championed for generations.”

The gaming activation will feature a high-tech mobile gaming trailer outfitted with gaming stations, virtual reality experiences, and a professional racing simulator. A dedicated event tent located alongside the trailer will expand the experience with additional console stations for free play, spectating, and community engagement throughout the Jamboree.

PlayVS aims to deliver a memorable gaming experience that brings together the excitement of play with the values of leadership, teamwork, and community.

About PlayVS

PlayVS is North America’s leading scholastic and collegiate gaming platform, helping students unlock the educational, social, and personal benefits of competitive gaming. The company brings together students, coaches, educators, and schools through structured, education-aligned competition across K–12 and college. PlayVS is the official esports partner of the NFHS Network, the Special Olympics, and state and regional organizations across the U.S. and Canada. To learn more, visit playvs.com.

Media Contact:
press@playvs.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/playvs-and-scouting-america-announce-gaming-activation-at-the-2026-national-jamboree-302831072.html

SOURCE PlayVS

Continue Reading

Trending